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Abstract: 
Ketamine produces effects in healthy humans that resemble the positive, negative and 
cognitive symptoms of schizophrenia. We investigated the effect of ketamine administration 
on brain activity as indexed by blood oxygen level dependent (BOLD) signal change response, 
and its relationship to ketamine-induced subjective changes, including perceptual distortion. 
Thirteen healthy participants volunteered for the study. All underwent a 15-minute functional 
MRI acquisition with a ketamine infusion commencing after 5 minutes (approx 0.26mg/Kg 
over 20s followed by an infusion of approx. 0.42mg/Kg/Hr). Following the scan, participants 
self-rated ketamine-induced effects using the Psychotomimetic States Inventory (PSI). 
Ketamine led to widespread cortical and subcortical increases in BOLD response (FWE-
corrected p < 0.01).  Self-rated perceptual distortions and delusional thoughts correlated with 
increased BOLD response in the paracentral lobule (FWE-corrected p < 0.01). The findings 
suggest that BOLD increases in parietal cortices reflect ketamine effects on circuits that 
contribute to its capacity to produce perceptual alterations and delusional interpretations. 
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Introduction 
Ketamine is an uncompetitive N-methyl-D-aspartate (NMDA) glutamate receptor antagonist that 
produces effects in healthy volunteers, which resemble the positive, negative and cognitive 
symptoms of schizophrenia (Krystal et al., 2005). The brain basis for these subjective changes is 
only beginning to be understood (Deakin et al., 2008, Anticevic et al., 2012, Stone et al., 2012). 
Animal pharmacological magnetic resonance imaging (PhMRI) studies have reported increases of 
blood-oxygen level dependent (BOLD) signal in frontal, hippocampal and thalamic regions 
following ketamine administration (Littlewood et al., 2006). In humans, phMRI studies have 
reported ketamine-induced elevations in mid-posterior cingulate, thalamus, and temporal cortex 
BOLD, which correlated with brief psychiatric rating scale scores, a decrease in subgenual 
cingulate BOLD, which correlated with dissociative effects (Deakin et al., 2008), and decreased 
posterior cingulate and medial prefrontal deactivations during a working memory task which 
correlated with negative symptom ratings (Anticevic et al., 2012). These findings are supported by 
earlier studies of regional brain metabolism following ketamine administration using 14C-2-
deoxyglucose (2DG) and FDG positron emission tomography (PET), showing increase in uptake in 
medial prefrontal, ventrolateral orbital, cingulate, and retrosplenial cortices in rats (Duncan et al., 
1998), and thalamus, frontal and parietal cortices in humans (Langsjo et al., 2004). 
 
We recently developed an improved method for detecting ketamine-induced change in BOLD 
response, accounting for the modeled neural response to acute administration of ketamine as a 
single vector as well as nuisance variables (head movement and scanner drift) (De Simoni et al., 
2012). In developing the methods, we used a dose of ketamine that produced relatively mild 
dissociative effects (target plasma level: 75ng/mL), and, perhaps for this reason, we found no 
significant relationship between ketamine-induced changes in BOLD response, and 
psychopathology, despite high reliability of both the phMRI and psychopathology ratings (De 
Simoni et al., 2012). In this study, we repeated our earlier study design, but used a higher dose of 
ketamine (target plasma dose of 150ng/mL), to investigate the relationship between ketamine-
induced psychopathology and BOLD response. 
 
Methods 
Thirteen healthy male volunteers (age 18-50) were recruited by advertisement. Exclusion criteria 
included positive urine drug screen for drugs of abuse, the consumption of more than 5 cups of 
coffee per day, smoking more than 5 cigarettes per day, taking prescription drugs, and any history of 
mental illness, or serious medical condition that, in the opinion of the study doctors, prevented their 
participation in the study. Fulfillment of inclusion and exclusion criteria was assessed by a 
psychiatrist who completed a full psychiatric, neurological and medical examination of each 
participant (including electrocardiogram and urine drug screen). Written informed consent was 
provided by all participants prior to their inclusion in the study, which was approved by the East 
London Research Ethics Committee 
 
Study design 
The study was an open-label, within-subjects design. Prior to entering the scanner, participants rated 
their baseline psychopathology using the Psychotomimetic States Inventory (PSI; 48 items 
consisting of six subscales - Delusional Thinking, Perceptual Distortion, Cognitive Disorganisation, 
Anhedonia, Mania and Paranoia) (Mason et al., 2008). All participants then underwent MRI 
scanning on a 3.0T GE HDx scanner (GE Medical Systems, Milwaukee, WI, USA). After an initial 
localizer scan we acquired structural images including an axial 2D T2-weighted fast spin echo scan 
and an axial fast fluid-attenuated inversion recovery scan (total scan time = 5 min). These were 
followed by a whole-brain three-dimensional coronal inversion recovery prepared spoiled gradient 
echo (IR-SPGR) scan, giving isotropic 1.1-mm voxels in a scan time of approximately 6 min (echo 
time (TE) = 2.82 msec; repetition time (TR) = 6.96 msec; inversion time = 450 msec; excitation flip 
angle = 20°).  
 Participants then underwent a 15 minute BOLD acquisition using gradient echo EPI (450 image 
volumes of 38 slices with 3mm thickness, interslice gap = 0.3mm; TE/TR = 30/2000ms; flip angle 
(FA) = 75°; in-plane voxel size = 3.3mm; matrix size = 64×64; field of view = 21.1 x 21.1cm). 
During this acquisition they were asked to look at a small fixation cross displayed on the screen in 
front of them. A dynamically modeled intravenous infusion of ketamine was commenced 5 minutes 
after the start of the BOLD acquisition (target plasma level: 150ng/mL) driven by a pump situated 
outside the scanner room, with participants having no indication that the infusion had started. The 
rate of infusion was controlled over the full period of infusion by a laptop computer running 
Stanpump software (www.opentci.org) driving a Graseby 3400 syringe-driver. The rate was 
determined based on the pharmacodynamic properties of ketamine from the “Clements 250 model” 
(Clements and Nimmo, 1981, Absalom et al., 2007). In practice, this translated to a rapid bolus over 
20 seconds of approx. 0.26mg/Kg followed by a slow infusion of approx. 0.42mg/Kg/Hr. 
 
After being disconnected from the ketamine infusion and leaving the scanner, blood levels for 
ketamine and norketamine were taken, following which, participants rated peak ketamine-induced 
effects using the PSI. Corrected PSI subscale scores were calculated by dividing the total subscale 
score by the number of items for each subscale (range for each subscale after correction – 0-3). 
 
Data analysis 
Data were analysed using SPM8 (Wellcome Department of Cognitive Neurology, London, UK). 
Slice-timing correction and two-pass realignment of the time series image volumes was followed by 
spatial normalisation to the SPM EPI template. Data were smoothed using an 8mm full width at half 
maximum (FWHM) Gaussian kernel. A high-pass filter of 1200s was applied to minimise the 
influence of very low frequency noise present in phMRI BOLD data. 
 
The phMRI response to ketamine was modeled using a gamma-variate regressor based on the 
results of a previously published ketamine phMRI study in humans (Deakin et al., 2008) and 
validated in an independent cohort (De Simoni et al., 2012). The regressor was flat for the first 5 
minutes and then rose after commencement of the ketamine infusion, peaking at 240s, and 
decreasing to 50% of its maximum by 10 minutes post-infusion. In addition, a Singular Value 
Decomposition (SVD) of the three translational and three rotational head movement traces, a white 
matter regressor, and a linear drift regressor were included as nuisance variables. 
  
Whole brain, voxel-wise contrast maps were generated for each subject and analysed in a single-
sample group analysis to investigate the effect of ketamine on BOLD response. For statistical 
inference we used cluster corrected statistics at family-wise error (FWE) p < 0.05 with a cluster-
forming threshold of p<0.001 at the voxel level. The relationship between ketamine-induced BOLD 
response and psychopathology was investigated by regression of the change in PSI subscales from 
baseline against whole brain individual t-contrasts, using the same statistical thresholds. 
 
Results 
Ketamine administration led to a significant (p < 0.05) [mean(SD)] increase from baseline in 
subjective ratings on Perceptual Distortion [0.74(0.47)], Cognitive Disorganisation [0.72(0.70)], 
Mania [0.48(0.45)], Anhedonia [0.41(0.34)] and Delusional Thinking [0.29(0.40)] PSI subscales, 
but there was no significant increase in PSI-rated Paranoia [0.08(0.15)]. With the exception of 
Anhedonia and Paranoia, these were significantly greater than the subjective effects reported with 
the lower target dose of 75 ng/mL plasma ketamine from our earlier study (p<0.05, Figure 1) (De 
Simoni et al., 2012). After leaving the scanner, ketamine and norketamine [mean(SD)] levels were 
113.8(27.6) ng/ml and 56.5(14.3) ng/ml respectively. There were no correlations between ketamine 
or norketamine levels and clinical rating scales. 
 
Ketamine led to widespread, significant increases in BOLD response in multiple cortical and 
subcortical brain regions including cingulate gyrus, hippocampus, insula, thalamus and midbrain 
(cluster size = 57367 voxels; FWE-corrected p < 0.001; Figure 2). Ketamine led to a significant 
decrease in BOLD response in a single cluster centred on the subgenual anterior cingulate (cluster 
peaks at [-2, 30, -10],[ 0, 38 -4],[ 6,34, 12]; cluster size = 291 voxels; FWE-corrected p=0.008). 
With whole-brain regression analysis, increase in PSI Perceptual Distortion from baseline was 
positively related to one cluster of increased BOLD following ketamine administration – in the 
paracentral lobule (cluster peaks at [-6,-24,52],[ -12,-22,72],[ 4,-28,62]; cluster size = 376 voxels; 
FWE-corrected p = 0.001). Change in PSI Delusional Thinking from baseline was also positively 
related to one cluster of increased BOLD following ketamine administration in an overlapping 
region (cluster peaks at [8,-20,58],[-2,-24,70],[8,-30,66]; cluster size = 489 voxels; FWE-corrected 
p < 0.001). It should be noted that PSI Delusional Thinking and PSI Perceptual distortion were 
correlated (r = 0.63, p < 0.05). There were no other correlations of BOLD changes with PSI 
subscales. 
 
Conclusions 
This study shows a relationship between ketamine-induced perceptual distortion and changes in 
BOLD activation. The study also replicates the earlier findings that ketamine administration 
increases cortical BOLD response in humans, with good agreement on the regions affected (Deakin 
et al., 2008, De Simoni et al., 2012). The reduction in subgenual anterior cingulate cortex is notable 
in that it is in the same brain region as reported in three earlier studies (Deakin et al., 2008, De 
Simoni et al., 2012, Doyle et al., 2013), and is the only region in which a reduction in BOLD was 
seen using whole-brain analysis. It is interesting to note that ketamine-induced changes in blood 
flow measured using PET did not show any reductions (Langsjo et al., 2004). While these did not 
measure immediate change on bolus administration due to the poor temporal resolution of PET, it 
remains possible that the subgenual anterior cingulate changes measured with BOLD represent 
ketamine-induced changes in metabolism decoupled from blood flow. 
 
In this study, PSI-rated increases in perceptual distortion on the PSI rating scale were the strongest 
effects of ketamine. In comparison to our earlier, lower dose study (De Simoni et al., 2012), PSI 
ratings were significantly higher in all categories, but the pattern of ketamine-induced changes in 
PSI ratings was very similar, indicating that the PSI appears to be a robust marker of the effects of 
ketamine across different doses. Perceptual Distortion and Delusional Thinking were both 
associated with the ketamine-induced effects on BOLD response in the paracentral lobule in the 
body area (Penfield and Rasmussen, 1950). This area may be activated in response to ketamine-
induced alterations in body sensation and delusional interpretations of sensations. We also speculate 
that this account can also be interpreted within the forward model where a failure of feed forward 
inhibition alters the experience of sensory stimuli, including bodily sensations such that perceptions 
have an altered quality (Frith, 2005). Future investigations should assess the forward model account 
of experiences on ketamine by combining ketamine administration with experimental interventions 
such as passive control of movements (Blakemore et al., 2003).  
 
There are a number of potential limitations to the study. The perceptual effects of ketamine were 
scored retrospectively, rather than during the experience. We felt that this was unavoidable as rating 
experiences during the scan may have had an impact on the scan quality and possibly on BOLD 
response. Furthermore, during the experience, due to its intensity, participants may have found 
answering questions difficult or intrusive. In support of this approach, we have previously shown, 
using a lower dose of ketamine, that retrospective scoring using the PSI gives highly reliable ratings 
(ICC=0.93). A second issue is that the regions showing the greatest BOLD change following 
ketamine administration did not fully overlap with the regions associated with ketamine-induced 
perceptual changes. Thus, it appears that the effects of ketamine on BOLD associated with 
perceptual changes and delusional thinking are distinct from the main effects of ketamine on BOLD 
signal. Third, we did not have a placebo arm. However, participants were not aware when the 
ketamine was started, and our earlier placebo-controlled study using an identical design did not 
show any effect of placebo on BOLD signal in any brain region (Doyle et al., 2013). Lastly, 
ketamine blood levels were taken after disconnection of the ketamine infusion (required to allow 
participants to leave the scanner). As ketamine is rapidly cleared from the blood, this is likely to 
have led to an underestimation of ketamine blood levels, and a greater variance of measures. 
 
Although ketamine led to increases in subjective ratings in cognitive disorganization, and mania, 
these were not related to any changes in BOLD. Thus, it is possible that these effects may arise 
through other mechanisms, such as ketamine-induced alterations in brain connectivity (Niesters et 
al., 2012, Scheidegger et al., 2012, Driesen et al., 2013). Future studies in our laboratory will 
investigate this possibility. 
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 Figure 1 Subjective ratings of psychopathology (mean PSI subscales with error bars showing 
standard error) pre- and post-ketamine administration (A – Anhedonia; CD – Cognitive 
Disorganisation; DT – Delusional Thinking; M – Mania; P – Paranoia; PD – Perceptual Distortion). 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
Figure 2 Main effect of ketamine on BOLD response (upper row). Image shows significant 
increases (red/yellow) at p<0.05 cluster-corrected overlaid on the high resolution MNI template 
brain from MRIcroN (www.mricro.com). A single cluster of decreased BOLD response following 
ketamine administration is shown in blue (whole-brain cluster-corrected p < 0.05). Brain slices 
(from left to right) are at MNI z values of -20 – 70 at 10mm intervals. The lower row shows the 
clusters of significant association between BOLD signal following ketamine and self-rated 
perceptual distortion and delusional thinking (whole-brain cluster-corrected p < 0.05).  
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